Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABBV-319 by AbbVie for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
ABBV-319 is under clinical development by AbbVie and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
ABBV-319 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
ABBV-319 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
ABBV-319 by AbbVie for Follicular Lymphoma: Likelihood of Approval
ABBV-319 is under clinical development by AbbVie and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I...
ABBV-319 by AbbVie for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ABBV-319 is under clinical development by AbbVie and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...